TMCI Overview

Key Data

  • Open $28.25
  • Day Range 28.20 - 30.85
  • 52 Week Range 24.25 - 34.47
  • Market Cap $1.52B
  • Shares Outstanding 51.64M
  • Public Float 25.41M
  • Beta 1.05
  • Rev. per Employee N/A
  • P/E Ratio N/A
  • EPS -$0.08
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 53.67K 04/30/21
  • % of Float Shorted 0.21%
  • Average Volume 595.9K

Performance

5 Day
  • -11.00%

Recent News

  • MarketWatch
  • Dow Jones

Treace Medical Concepts started at overweight with $37 stock price target at J.P. Morgan

May. 18, 2021 at 7:27 a.m. ET by Tomi Kilgore

Treace Medical Concepts started at buy with $35 stock price target at Stifel Nicolaus

May. 18, 2021 at 6:41 a.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

No Headlines Available

Treace Medical Concepts Inc.

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.